Determination of Disease-Specific Protein Aggregates in Stool Samples

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention provides a method for detecting and quantifying disease-specific protein aggregates, such as amyloid-beta (A-beta) and alpha-synuclein, in stool samples. By immobilizing specific antibodies on a substrate and using detection probes, the method allows for the non-invasive identification and measurement of these protein aggregates, which are biomarkers for neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease (PD). The process offers high specificity and sensitivity using advanced fluorescence-based detection, surpassing conventional techniques that require invasive sampling of body fluids or tissue.

Use CasesContent extracted from patent full text and abstract with AI.

• Early diagnosis of Alzheimer's disease and Parkinson's disease using stool samples.
• Monitoring progression of neurodegenerative diseases in patients through repeated non-invasive sampling.
• Screening large populations for early-stage neurodegenerative disorders without the need for invasive procedures.
• Selection or stratification of candidates for clinical trials based on biomarker levels in stool.
• Evaluating the effectiveness of therapeutic interventions or drugs by measuring biomarker changes over time in stool samples.
• Remote or home-based sample collection for neurodegenerative disease monitoring and research studies.

BenefitsContent extracted from patent full text and abstract with AI.

• Non-invasive and painless sample collection, improving patient comfort and compliance compared to blood or spinal fluid sampling.
• Enables the detection and quantification of disease-relevant protein aggregates with high specificity and sensitivity.
• Facilitates early and potentially more accurate diagnosis of Alzheimer's and Parkinson's diseases.
• Reduces the need for skilled medical staff during sample collection, as stool can be collected at home.
• Allows for repeated, longitudinal monitoring of disease biomarkers without patient stress or inconvenience.
• Easily scalable for large-scale screening and population health studies.
• Supports personalized medicine approaches by tracking therapy responses in individuals.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to processes for selectively quantifying A-beta and/or alpha-synuclein aggregates, comprising the immobilization of anti-A-beta and/or alpha-synuclein antibodies on a substrate, the application of the stool sample to be examined onto the substrate, the addition of probes marked for detection, which are marking said probes by specifically binding to A-beta and/or alpha-synuclein aggregates, and the detection of the marked aggregates.